An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases

In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis....

Descripción completa

Detalles Bibliográficos
Autores principales: Filgueira, Lázaro Manuel, Cervantes, Julio Betancourt, Lovelle, Orlando Adolfo, Herrera, Carlos, Figueredo, Carlos, Caballero, Jorge Alain, Sánchez, Naivy, Berrio, Jorge, Lorenzo, Geidy, Cepeda, Meylan, Ramos, Mayra, Saavedra, Danay, Añe-Kouri, Ana Laura, Mazorra, Zaima, Leon, Kalet, Crombet, Tania, Caballero, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784786/
https://www.ncbi.nlm.nih.gov/pubmed/33397150
http://dx.doi.org/10.2217/imt-2020-0235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784786/
https://www.ncbi.nlm.nih.gov/pubmed/33397150
http://dx.doi.org/10.2217/imt-2020-0235

Ejemplares similares